Ascendis Pharma A/S (ASND)
- Previous Close
154.43 - Open
155.20 - Bid 158.03 x 600
- Ask 163.69 x 600
- Day's Range
154.64 - 162.26 - 52 Week Range
111.09 - 183.00 - Volume
488,982 - Avg. Volume
531,843 - Market Cap (intraday)
9.752B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-6.53 - Earnings Date May 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
220.52
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
ascendispharma.comRecent News: ASND
View More
Performance Overview: ASND
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASND
View MoreValuation Measures
Market Cap
9.75B
Enterprise Value
10.12B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.89
Price/Book (mrq)
--
Enterprise Value/Revenue
24.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.67%
Return on Assets (ttm)
-22.39%
Return on Equity (ttm)
--
Revenue (ttm)
368.7M
Net Income Avi to Common (ttm)
-341.68M
Diluted EPS (ttm)
-6.53
Balance Sheet and Cash Flow
Total Cash (mrq)
517.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-133.44M